JAZZ Jazz Pharmaceuticals plc

147.89
+0.11  (0%)
Previous Close 147.78
Open 147.76
Price To book 4.04
Market Cap 8883007378
Shares 60,064,963
Volume 187,044
Short Ratio 4.37
Av. Daily Volume 468,687

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171079523
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171076479
  3. 8-K - Current report 171066531
  4. 8-K - Current report 171047272
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015756

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL received October 11, 2010.
JZP-6
Fibromyalgia
Phase 2 enrollment initiation announced February 8, 2017.
JZP-110
Excessive Sleepiness in Parkinson's Disease
Phase 2/3 positive data released April 24, 2017. sNDA filing due 4Q 2017.
Xyrem
Pediatric narcolepsy patients with cataplexy
Phase 3 data released March 20, 2017 - primary endpoints met.
JZP-110
Excessive sleepiness associated with obstructive sleep apnea
Phase 3 data released April 26, 2017. NDA to be filed late 2017.
JZP-110
Excessive sleepiness associated with narcolepsy
Phase 3 trial initiated 3Q 2016.
Defibrotide
VOD in high-risk patients following hematopoietic stem cell transplantation
Approval announced August 3, 2017.
Vyxeos
Acute myeloid leukemia